8-K: Intra-Cellular Therapies Announces Positive Phase 3 Results for Lumateperone in Major Depressive Disorder

Intra-Cellular Therapies' lumateperone 42 mg demonstrated statistically significant and clinically meaningful improvements in major depressive disorder symptoms when used as an adjunctive therapy to antidepressants in a Phase 3 trial.

Summary

• Intra-Cellular Therapies announced positive topline results from its Phase 3 Study 501, evaluating lumateperone 42 mg as an adjunctive therapy for major depressive disorder (MDD).
• The study met its primary endpoint, showing a statistically significant reduction in the Montgomery Asberg Depression Rating Scale (MADRS) total score compared to placebo at Week 6.
• The least squares mean reduction from baseline for lumateperone was 14.7 points, compared to 9.8 points for placebo, a difference of -4.9 points (p<0.0001).
• Lumateperone also met the key secondary endpoint, demonstrating a statistically significant reduction in the Clinical Global Impression Scale for Severity of Illness (CGI-S) score compared to placebo at Week 6 (p<0.0001).
• Statistically significant efficacy was observed as early as Week 1 and maintained throughout the study for both primary and secondary endpoints.
• Patients also reported significant improvements in depressive symptoms as measured by the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR-16) (p<0.0001).
• The drug was generally safe and well-tolerated, with the most common adverse events being dry mouth (10.8%), fatigue (9.5%), and tremor (5.0%).
• These adverse events were mostly mild to moderate and resolved quickly, consistent with previous studies of lumateperone.

Sentiment

Score: 9

Explanation: The document presents very positive results from a Phase 3 trial, with strong efficacy and a favorable safety profile, suggesting a high likelihood of regulatory approval and commercial success. The management commentary is also very positive.

Positives

• Lumateperone demonstrated a statistically significant and clinically meaningful reduction in depressive symptoms when used as an adjunctive therapy.
• The drug showed efficacy as early as Week 1 and maintained it throughout the study.
• The safety and tolerability profile was favorable and consistent with previous studies.
• The results support the potential of lumateperone as a treatment option for MDD.
• The study showed a robust effect as an adjunctive treatment to antidepressants in patients with MDD who had inadequate response to antidepressant therapy.

Negatives

• The most common adverse events were dry mouth, fatigue, and tremor, although these were mostly mild to moderate.
• The study only evaluated lumateperone as an adjunctive therapy, not as a monotherapy for MDD.

Risks

• There are no guarantees that CAPLYTA will be commercially successful.
• The company may encounter issues, delays, or other challenges in commercializing CAPLYTA.
• The COVID-19 pandemic may negatively impact the company's commercial plans and sales for CAPLYTA.
• The COVID-19 pandemic may negatively impact the conduct of, and the timing of enrollment, completion and reporting with respect to, the company's clinical trials.
• CAPLYTA may not receive adequate reimbursement from third-party payors.
• The degree to which CAPLYTA receives acceptance from patients and physicians for its approved indications is uncertain.
• There are challenges associated with execution of the company's sales activities.
• Results achieved in CAPLYTA in the treatment of schizophrenia and bipolar depression following commercial launch of the product may be different than observed in clinical trials, and may vary among patients.
• There are challenges associated with supply and manufacturing activities.
• Impacts on the company's business, including on the commercialization of CAPLYTA and the company's clinical trials, as a result of the conflict in Ukraine are possible.
• The company may encounter unexpected safety or tolerability issues with CAPLYTA following commercial launch.
• Other product candidates may not be successful or may take longer and be more costly than anticipated.
• Product candidates that appeared promising in earlier research and clinical trials may not demonstrate safety and/or efficacy in larger-scale or later clinical trials or in clinical trials for other indications.
• The company's proposals with respect to the regulatory path for its product candidates may not be acceptable to the FDA.
• The company relies on collaborative partners and other third parties for development of its product candidates.

Future Outlook

Topline results from the second Phase 3 study, Study 502, are anticipated late in the second quarter of this year. The company aims to further establish CAPLYTA as a first-choice treatment across mood disorders.

Management Comments

• Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies, stated that the positive Phase 3 results in MDD represent a significant step towards their goal of further establishing CAPLYTA as a first-choice treatment across mood disorders.
• Dr. Suresh Durgam, Executive Vice President, Chief Medical Officer of Intra-Cellular Therapies, noted that lumateperone demonstrated a robust effect as an adjunctive treatment to antidepressants in patients with MDD who had inadequate response to antidepressant therapy.

Industry Context

The positive results for lumateperone in MDD are significant given the high prevalence of the condition and the need for more effective treatments with fewer side effects. This could position CAPLYTA as a strong contender in the market for adjunctive MDD therapies.

Comparison to Industry Standards

• The reported 4.9 point reduction in MADRS score compared to placebo is clinically meaningful and aligns with efficacy benchmarks for antidepressant medications.
• The effect size of 0.61 for the primary endpoint and 0.67 for the secondary endpoint are considered robust and comparable to other successful treatments in this space.
• The safety profile of lumateperone, with mostly mild to moderate adverse events, is favorable compared to some other antipsychotics used in adjunctive therapy for MDD.
• Companies like Eli Lilly (with Cymbalta) and Otsuka (with Abilify) have established adjunctive treatments for MDD, and the results of this study position Intra-Cellular Therapies to compete in this market.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical trial results.
• Patients with MDD may benefit from a new treatment option with a favorable safety profile.
• Physicians may be more likely to prescribe lumateperone if it receives regulatory approval.
• Employees of Intra-Cellular Therapies may experience increased job security and opportunities for growth.

Next Steps

• The company anticipates topline results from the second Phase 3 study, Study 502, late in the second quarter of this year.
• The company will continue to pursue regulatory approval for lumateperone as an adjunctive therapy for MDD.
• The company will host a live conference call and webcast to discuss the results of Study 501.

Key Dates

Keywords

lumateperone, major depressive disorder, MDD, adjunctive therapy, antidepressants, clinical trial, Phase 3, CAPLYTA, psychiatric disorders, neuropsychiatric